Stent maker's rating is raised Standard  amp; Poor's raised its outlook on Boston Scientific Corp. to positive from stable, citing its recovery of market share for its drug-coated Taxus cardiac stent after recalls that began in July. The debt rating agency said the upgrade reflects the Natick company's  quot;surprisingly rapid recovery quot; of market share for Taxus, and its diverse product line. Last week, Boston Scientific ...